Study of Sacituzumab Govitecan Versus Physician's Choice of Treatment in Participants With Urothelial Cancer That Cannot Be Removed or Has Spread

NCT04527991 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

712

Enrollment

INDUSTRY

Sponsor class

Conditions

Locally Advanced or Metastatic Unresectable Urothelial Cancer

Interventions

DRUG: Sacituzumab Govitecan-hziy
DRUG: Paclitaxel
DRUG: Docetaxel
DRUG: Vinflunine

Sponsor

Gilead Sciences